Opioid Use Disorder and Brixadi Approval: Interview with Dr. Joshua Cohen, Chief Medical Officer at Braeburn

Xtalks Life Science Podcast

English - July 12, 2023 09:00 - 15 minutes - 10.5 MB
Life Sciences Science pharma pharmaceuticals biotech biotechnology medical device life science drug safety clinical research clinical trials drug development Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Developing More Affordable Cellular Immunotherapies: Interview with CytoMed Therapeutics

Next Episode: Biosimilars and the Problem with PBMs: Interview with Juliana M. Reed, Executive Director of the Biosimilars Forum

In this episode, Sarah interviews Dr. Joshua Cohen, Chief Medical Officer at Braeburn, who talks about the stigma associated with opioid use disorder (OUD), and how our treatment of this condition is changing.

Dr. Cohen talks about the recent FDA approval of Brixadi, the first long-acting buprenorphine treatment for opioid use disorder that has both weekly and monthly dosing options, and explains the technology behind its extended-release formula.

Read the full article here:

Brixadi Is a New Long-Acting Buprenorphine Treatment Against OUD

For more life science and medical device content, visit the Xtalks Vitals homepage.

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Social Post:

Twitter Mentions

@xtalks